AI Article Synopsis

  • The study assessed the effectiveness of a combined pharmacogenomic test and single-gene guidelines in predicting treatment outcomes for patients with major depressive disorder (MDD).
  • It used data from the GUIDED randomized-controlled trial, which involved patients with MDD who had already failed at least one medication, analyzing how gene-drug interactions correlated with patient symptoms and medication levels.
  • The findings showed that the combinatorial test was the only strong predictor of patient outcomes, outperforming the single-gene guidelines, although both tests were effective for predicting medication blood levels separately.

Article Abstract

We evaluated the clinical validity of a combinatorial pharmacogenomic test and single-gene Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines against patient outcomes and medication blood levels to assess their ability to inform prescribing in major depressive disorder (MDD). This is a secondary analysis of the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, which included patients with a diagnosis of MDD, and ≥1 prior medication failure. The ability to predict increased/decreased medication metabolism was validated against blood levels at screening (adjusted for age, sex, smoking status). The ability of predicted gene-drug interactions (pharmacogenomic test) or therapeutic recommendations (single-gene guidelines) to predict patient outcomes was validated against week 8 outcomes (17-item Hamilton Depression Rating Scale; symptom improvement, response, remission). Analyses were performed for patients taking any eligible medication (outcomes N=1,022, blood levels N=1,034) and the subset taking medications with single-gene guidelines (outcomes N=584, blood levels N=372). The combinatorial pharmacogenomic test was the only significant predictor of patient outcomes. Both the combinatorial pharmacogenomic test and single-gene guidelines were significant predictors of blood levels for all medications when evaluated separately; however, only the combinatorial pharmacogenomic test remained significant when both were included in the multivariate model. There were no substantial differences when all medications were evaluated or for the subset with single-gene guidelines. Overall, this evaluation of clinical validity demonstrates that the combinatorial pharmacogenomic test was a superior predictor of patient outcomes and medication blood levels when compared with guidelines based on individual genes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2020.113649DOI Listing

Publication Analysis

Top Keywords

blood levels
28
combinatorial pharmacogenomic
24
pharmacogenomic test
24
single-gene guidelines
20
patient outcomes
16
medication blood
12
outcomes
8
clinical validity
8
test single-gene
8
outcomes medication
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!